Cancer Care and the Importance of AI in Furthering Oncology

By HEOR Staff Writer

May 2, 2024

Introduction: The Emergence of AI in Oncology

In recent years, artificial intelligence (AI) has provided significant advancements in healthcare, notably in oncology. As AI tools become more accessible, medical professionals are increasingly turning to them for assistance with complex medical information. Among these tools, large language models (LLMs) such as GPT-3.5 and GPT-4 are not only enhancing search capabilities but are also exhibiting qualities akin to human intelligence.

Evaluating AI Performance in Oncology

A recent study aimed to assess the accuracy, confidence, and consistency of responses from state-of-the-art LLMs when addressing over 2000 oncology-related questions. This research represents a pioneering comparison of LLMs in any medical specialty. GPT-4, in particular, demonstrated superior performance, suggesting its potential as a valuable tool for oncology professionals.

Figure 1. Overall Model Performance on Standardised Oncology Questions.

The Limitations of Current AI Models

Despite their impressive capabilities, LLMs are not without flaws. Findings revealed significant error rates and biases, particularly regarding female-predominant malignancies. These biases raise concerns about the reliability of AI in clinical settings and underscore the need for further refinement of these technologies.

Enhancing AI Reliability in Medical Practice

To improve the reliability of AI in medical practice, the study explored strategies such as self-assessed confidence and response consistency. While these methods can increase accuracy, they also expose the limitations of current AI models, including overconfidence and persistent inaccuracies.

AI’s Clinical Utility

Validating AI tools against clinical examinations is only the first step. Ensuring their safety and efficacy in real-world clinical settings is paramount. While AI has shown promise in supporting oncologists, widespread adoption will require rigorous validation and continuous evaluation of these tools’ strengths and limitations.

Conclusion:

In conclusion, the integration of AI in oncology offers a compelling adjunct to the expertise of healthcare providers. While AI’s current limitations necessitate cautious application, its ability to process vast amounts of data and generate insights holds the potential to significantly enhance clinical decision-making. It is crucial to recognise that AI acts as a complement, not a replacement, to the nuanced judgement and compassionate care that only human professionals can provide. As we continue to refine AI technologies, their role in supporting and extending the capabilities of oncology specialists will undoubtedly become an indispensable asset in the fight against cancer.

Reference url

Recent Posts

Health Investment Returns: Harnessing Health as a Strategic Economic Asset

By João L. Carapinha

November 18, 2025

Health as a Strategic Economic Imperative A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recent EFPIA Guest Blog by Michael Oberreiter frames he...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gram-Negative Infections
Emblaveo Approved for MDR Gram-Negative Infections Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avibactam) for financing under Decree-Law No. 97/2015....
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line Therapy

By HEOR Staff Writer

November 17, 2025

Sacituzumab Govitecan Shows Promise in First-Line TNBC Therapy Sacituzumab govitecan for TNBC represents a major step forward in treating untreated